Resources and management strategies for the use of radiotherapy in the treatment of lung cancer in Central and Eastern European countries: Results of an International Atomic Energy Agency (IAEA) survey

Lung Cancer

Volumn 56, Issue 2, 2007, Pages 235-245

  Kepka, Lucyna ^a   Danilova, Vera ^b   Saghatelyan, Tatul ^c   Bajcsay, Andras ^d   Utehina, Olga ^e   Stojanovic, Suzana ^f   Yalman, Deniz ^g   Demiral, Ayse ^h   Bondaruk, Olga ⁱ   Kuddu, Maire ^j   Jeremic, Branislav ^k  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c Department of Radiotherapy   (Armenia)

^d NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^e RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^f INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^g EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^h DOKUZ EYLUL UNIVERSITY   (Turkey)

ⁱ STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^j North Estonian Regional Hospital   (Estonia)

^k INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

more..

Author keywords

Developing countries; NSCLC; Patterns of care survey; Radiotherapy; SCLC

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PLATINUM DERIVATIVE; VINCRISTINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; DEVELOPING COUNTRY; EASTERN EUROPE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE MANAGEMENT; HEALTH CARE UTILIZATION; HUMAN; LINEAR ACCELERATOR; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDICAL SPECIALIST; ONCOLOGY; PALLIATIVE THERAPY; PATIENT CARE; PRIORITY JOURNAL; QUESTIONNAIRE; RESOURCE ALLOCATION; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DATA COLLECTION; DEVELOPING COUNTRIES; EUROPE; HEALTH RESOURCES; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONAL AGENCIES; LUNG NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; RADIATION ONCOLOGY; RADIOTHERAPY;

EID: 34247152487     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.12.011     Document Type: Article

References (52)

1. Movsas B., Moughan J., Komaki R., Choy H., Byhardt R., Langer C., et al. Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol 21 (2003) 4553-4559
2. Langer C.J., Moughan J., Movsas B., Komaki R., Ettinger D., Owen J., et al. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?. Lung Cancer 48 (2005) 93-102
3. Van Houtte P., Gregor A., and Philips P. An international survey of radiotherapy practise for radical treatment of non-small cell lung cancer. Lung Cancer 11 (1994) S129-S138
4. Levin V., and Tatsuzaki H. Radiotherapy services in countries in transition: gross national income per capita as a significant factor. Radiother Oncol 63 (2002) 147-150
5. Micke P., Faldum A., Metz T., Beeh K.M., Bittinger F., Hengstler J.G., et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer-what limits limited disease?. Lung Cancer 37 (2002) 271-276
6. Choy H., Yu S., Cmelak A.J., Mohr P.J., and Johnson D.H. Patterns of practice survey for non-small cell lung carcinoma in the US. Cancer 88 (2000) 1336-1346
7. Phlips P., Rocmans P., Vanderhoeft P., and Van Houtte P. Postoperative radiotherapy after pneumonectomy: impact of modern treatment facilities. Int J Radiat Oncol Biol Phys 27 (1993) 525-529
8. Senan S., De Ruysscher D., Giraud P., Mirimanoff R., and Budach V. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71 (2004) 139-146
9. Casas F., Vinolas N., Sanchez-Reyes A., Jorcano S., Planas I., Marruecos J., et al. Spanish patterns of care for 3D radiotherapy in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 65 (2006) 138-142
10. Tai P., Yu E., Battista J., and Van Dyk J. Radiation treatment of lung cancer-patterns of practice in Canada. Radiother Oncol 71 (2004) 167-174
11. Stout R., Barber P., Burt P., Hopwood P., Swindell R., Hodgetts J., et al. Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) versus external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Radiother Oncol 56 (2000) 323-327
12. Langendijk H., de Jong J., Tjwa M., Muller M., ten Velde G., Aaronson N., et al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. Radiother Oncol 58 (2001) 257-268
13. Bezjak A., Dixon P., Brundage M., Tu T., Palmer M.J., Blood P., et al. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys 54 (2002) 719-728
14. Macbeth F., Toy E., Coles B., Mewille A., and Eastwood A. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev 2 (2001) CD002143
15. Delaney G., Barton M., Jacob S., and Jalaludin B. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol 4 (2003) 120-128
16. Tyldesley S., Boyd C., Schulze K., Walker H., and Mackillop W.J. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys 49 (2001) 973-985
17. Slotman B.J., Antonisse I.E., and Njo K.H. Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. Radiother Oncol 41 (1996) 41-44
18. Cheung P.C., Mackillop W.J., Dixon P., Brundage M.D., Youssef Y.M., and Zhou S. Involved-field radiotherapy alone for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 48 (2000) 703-710
19. Rowell N.P., and Wiliams C.J. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev 2 (2001) CD002935
20. Sun L.M., Leung S.W., Wang C.J., Chen H.C., Fang F.-M., Huang E.-Y., et al. Concomitant boost radiation therapy for inoperable non-small-cell lung cancer: preliminary report of a prospective randomized study. Int J Radiat Oncol Biol Phys 47 (2000) 413-418
21. Lester J.F., Macbeth F.R., Brewster A.E., Court J.B., and Iqbal N. CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer. Lung Cancer 45 (2004) 237-242
22. Krol A.D., Aussems P., Noordijk E.M., Hermans J., and Leer J.W. Local irradiation alone for peripheral stage I lung cancer-could we omit the elective regional nodal irradiation?. Int J Radiat Oncol Biol Phys 34 (1996) 297-302
23. Bradley J.D., Wahab S., Lockett M.A., Perez C.A., and Purdy J.A. Elective nodal failures are uncommon in medically inoperable patients with stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int J Radiat Oncol Biol Phys 56 (2003) 342-347
24. Rosenzweig K.E., Sim S.E., Mychalczak B., Braban L.E., Schindelheim R., and Leibel S.A. Elective nodal irradiation in the treatment of non-small cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 50 (2001) 681-685
25. Chen M., Hayman J.A., Ten Haken R.K., Tatro D., Fernando S., and Kong F.M. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation?. Int J Radiat Oncol Biol Phys 64 (2006) 120-126
26. Kupelian P.A., Komaki R., and Allen M.P.H. Prognostic factors in the treatment of node-negative non-small-cell lung carcinoma with radiotherapy. Int J Radiat Oncol Biol Phys 36 (1996) 607-613
27. Jeremic B. Incidental irradiation of nodal regions at risk during limited-field radiotherapy (RT) in dose-escalation studies in non-small cell lung cancer (NSCLC): enough to convert no-elective into elective nodal irradiation (ENI)?. Radiother Oncol 71 (2003) 123-125
28. Giraud P., De Rycke Y., Lavole A., Milleron B., Cosset J.M., and Rosenzweig K.E. Probability of mediastinal involvement in non-small-cell lung cancer: a statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy?. Int J Radiat Oncol Biol Phys 64 (2006) 127-135
29. Curran W.J., Scott C.B., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22 (2003) 621
30. Fournel P., Perol M., Robinet G., Thomas P., Souquet J.P., Lena H., et al. A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non-small-cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study). Proc Am Soc Clin Oncol 20 (2001) 312
31. Zatloukal P., Petruzelka L., Zemanova M., Havel L., Pecen L., and Judas L. Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small-cell lung cancer. A randomized phase II study-long-term follow-up data. Lung Cancer 41 s2 (2003) 76
32. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential radiotherapy in combination with mitomycin, vindesine and cisplatin in unresctable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
33. Rowell N.P., and O'Rourke N.P. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 4 (2004) CD002140
34. Jeremic B., Shibamoto Y., Acimovic L., and Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage non-small-cell lung cancer. J Clin Oncol 13 (1995) 452-458
35. Jeremic B., Shibamoto Y., Acimovic L., and Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14 (1996) 1065-1070
36. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350 (2004) 351-360
37. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 352 (2005) 2589-2597
38. Waller D., Peake M.D., Stephens R.J., Gower N.H., Milroy R., Parmar M.K., et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26 (2004) 173-182
39. Berghmans T., Paesmans M., Meert A.P., Mascaux C., Lothaire P., Lafitte J.J., et al. Survival improvement in resectable non-small-cell lung cancer with (neo)adjuvant chemotherapy: results of a metaanalysis of the literature. Lung Cancer 49 (2005) 13-23
40. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet 352 (1998) 257-263
41. Trodella L., Granone P., Valente S., Valentini V., Balducci M., Mantini G., et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol 62 (2002) 11-19
42. Machtay M., Lee J.H., Shrager J.B., Kaiser L.R., and Glatstein E. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small cell lung cancer. J Clin Oncol 19 (2001) 3912-3917
43. Murray N., Coy P., Pater J.L., Hodson I., Arnold A., Zee B.C., et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11 (1993) 336-344
44. Jeremic B., Shibamoto Y., Acimovic L., and Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 15 (1997) 893-900
45. Takada M., Fukuoka M., Kawahara M., Sugiura T., Yokoyama A., Yokota S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20 (2002) 3054-3060
46. Jeremic B. Timing of concurrent radiotherapy and chemotherapy in limited-disease small-cell lung cancer: "meta-analysis of meta-analyses". Int J Radiat Oncol Biol Phys 64 (2006) 981-982
47. Pijls-Johannesma M.C.G., De Ruysscher D., Lambin P., Rutten I., and Vansteenkiste J.F. Early versus late chest radiotherapy for limited stage cell lung cancer. Cochrane Database Syst Rev 4 (2004) CD004700
48. Sundstrom S., Bremnes R.M., Kaasa S., Aasebo U., Hatlevoll R., Dahle R., et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vicristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20 (2002) 4665-4672
49. Stupp R., Monnerat C., Turrisi III A.T., Perry M.C., and Leyvraz S. Small cell lung cancer: state of the art and future perspectives. Lung Cancer 45 (2004) 105-117
50. Auperin A., Arriagada R., Pignon J.P., Le Pechoux C., Gregor A., Stephens R.J., et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission: a meta-analysis of individual data from 987 patients. N Engl J Med 341 (1999) 476-484
51. Jeremic B., Shibamoto Y., Nikolic N., Milicic B., Milisavljevic S., Dagovic A., et al. The role of radiation therapy in the combined modality treatment of patients with extensive disease small cell lung cancer: a randomised trial. J Clin Oncol 17 (1999) 2092-2099
52. Taylor K.M., Feldstein M.L., Skeel R.T., Pandya K.J., Ng P., and Carbone P.P. Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group Investigators. J Clin Oncol 12 (1994) 1796-1805